Raymond James & Associates Has $286,000 Stake in InflaRx (NASDAQ:IFRX)

Raymond James & Associates lifted its holdings in InflaRx (NASDAQ:IFRX) by 7.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 175,279 shares of the company’s stock after acquiring an additional 12,873 shares during the quarter. Raymond James & Associates owned approximately 0.39% of InflaRx worth $286,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. 683 Capital Management LLC raised its position in InflaRx by 17.5% in the 3rd quarter. 683 Capital Management LLC now owns 2,350,000 shares of the company’s stock valued at $7,003,000 after purchasing an additional 350,000 shares during the last quarter. Affinity Asset Advisors LLC raised its holdings in shares of InflaRx by 35.3% in the third quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company’s stock valued at $969,000 after buying an additional 84,897 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of InflaRx by 45.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 268,915 shares of the company’s stock valued at $801,000 after buying an additional 84,178 shares during the last quarter. Finally, Alps Advisors Inc. lifted its position in InflaRx by 109.4% during the 3rd quarter. Alps Advisors Inc. now owns 83,279 shares of the company’s stock worth $248,000 after buying an additional 43,501 shares in the last quarter. 42.39% of the stock is currently owned by institutional investors.

InflaRx Stock Performance

Shares of IFRX opened at $1.39 on Tuesday. The business’s fifty day moving average price is $1.53 and its two-hundred day moving average price is $1.58. The firm has a market capitalization of $81.85 million, a price-to-earnings ratio of -1.62 and a beta of 1.27. InflaRx has a 52 week low of $1.14 and a 52 week high of $5.20.

InflaRx (NASDAQ:IFRX) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, research analysts forecast that InflaRx will post -1 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research report on Friday, March 22nd.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.